Bausch & Lomb eye implant
This article was originally published in The Gray Sheet
Executive Summary
Firm's new drug application for its Retisert drug-delivery eye implant receives FDA approval for the treatment of chronic, non-infectious uveitis affecting the posterior segment of the eye. Bausch & Lomb is targeting a commercial launch in the second half of the year. The company estimates that posterior uveitis affects 800,000 people worldwide (1"The Gray Sheet" Jan. 31, 2005, p. 20)...